SPA
MRVI icon

Sherbrooke Park Advisers’s Maravai LifeSciences MRVI Stock Holding History

Sherbrooke Park Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,168
Closed -$29.1K – 681
2025
Q1 		$29.1K Sell
13,168
-1,190
-8% -$4.7K 0.01% 562
2024
Q4 		$78.3K Buy
+14,358
New +$92.4K 0.03% 691
2024
Q1 		– Sell
-38,247
Closed -$251K – 947
2023
Q4 		$251K Buy
38,247
+23,976
+168% +$155K 0.12% 282
2023
Q3 		$143K Buy
+14,271
New +$157K 0.05% 427
2023
Q1 		– Sell
-16,900
Closed -$242K – 276
2022
Q4 		$242K Buy
+16,900
New +$266K 0.18% 221

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sherbrooke Park Advisers's MRVI Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 13,168 shares — an estimated $29.1K sold.

Sherbrooke Park Advisers first reported a position in MRVI in Q4 2022 and held it in 5 quarters. The position peaked at $251K in Q4 2023. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,168 Maravai LifeSciences shares in Q2 2025, an estimated $29.1K.
  • Sherbrooke Park Advisers first reported a position in Maravai LifeSciences in Q4 2022 and held it in 5 quarters.
  • Sherbrooke Park Advisers's Maravai LifeSciences position peaked at $251K in Q4 2023.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.